Clinical end points in baroreflex activation therapy: what do we need to know?

References

• Kearney PM, Whelton M, Reynolds K, Muntner P, Whelton PK, He J. Global burden of hypertension: analysis of worldwide data. Lancet 365(9455), 217–223 (2005).
   PubMed Web of Science ®Google Scholar
• Guyton AC, Hall JE, Coleman TG, Manning Jr RD, Norman Jr RA. The dominant role of the kidneys in long-term arterial pressure regulation in normal and hypertensive states. In: Hypertension: Pathophysiology, Diagnosis, and Management. Laragh JH, Brenner BM (Eds). Raven Press, New York, NY, USA, 1311–1326 (1995).
   Google Scholar
• De Leeuw PW, Birkenhäger WH. Renal hemodynamics and glomerular filtration in essential hypertension; effects of treatment. In: Assessment of Hypertensive Organ Damage. Hansson L, Birkenhäger WH (Eds). Elsevier Science BV, Amsterdam, The Netherlands, 345–363 (1997).
   Google Scholar
• Mancia G, Mark AL. Arterial baroreflexes in humans. In: Handbook of Physiology, Section 2: The Cardiovascular System. Shepherd JT, Abboud FM (Eds). American Physiological Society, Bethesda, MD, USA, 775–793 (1983).
   Google Scholar
• Sleight P. Nonpharmacological treatments for hypertension. J. Hypertens. 30(8), 1516–1517 (2012).
   PubMedGoogle Scholar
• Esler M, Jennings G, Korner P et al. Assessment of human sympathetic nervous system activity from measurements of norepinephrine turnover. Hypertension 11(1), 3–20 (1988).
   PubMed Web of Science ®Google Scholar
• Seals DR, Esler MD. Human ageing and the sympathoadrenal system. J. Physiol. (Lond.) 528(Pt 3), 407–417 (2000).
   Google Scholar
• Grassi G. Assessment of sympathetic cardiovascular drive in human hypertension: achievements and perspectives. Hypertension 54(4), 690–697 (2009).
   PubMed Web of Science ®Google Scholar
• Yamada Y, Miyajima E, Tochikubo O, Matsukawa T, Ishii M. Age-related changes in muscle sympathetic nerve activity in essential hypertension. Hypertension 13(6 Pt 2), 870–877 (1989).
   PubMed Web of Science ®Google Scholar
• Grassi G, Cattaneo BM, Seravalle G, Lanfranchi A, Mancia G. Baroreflex control of sympathetic nerve activity in essential and secondary hypertension. Hypertension 31(1), 68–72 (1998).
   PubMed Web of Science ®Google Scholar
• Grassi G, Esler M. How to assess sympathetic activity in humans. J. Hypertens. 17(6), 719–734 (1999).
   PubMed Web of Science ®Google Scholar
• Wallin BG, Thompson JM, Jennings GL, Esler MD. Renal noradrenaline spillover correlates with muscle sympathetic activity in humans. J. Physiol. (Lond.) 491(Pt 3), 881–887 (1996).
   Google Scholar
• Esler M, Lambert G, Jennings G. Regional norepinephrine turnover in human hypertension. Clin. Exp. Hypertens. A. 11(Suppl. 1), 75–89 (1989).
   PubMed Web of Science ®Google Scholar
• Cooper A. Guy’s hospital report. In: Reflexogenic Areas of the Cardiovascular System. Heymans C, Neil E (Eds). J&A Churchill, London, UK 457 (1858).
   Google Scholar
• Jordan J, Biaggioni I. Genetic influences on human baroreflex regulation. Auton. Neurosci. 172(1–2), 23–25 (2012).
   PubMedGoogle Scholar
• Korner P. Essential Hypertension and its Causes. Neural and Non-Neural Mechanisms. Oxford University Press, New York, NY, USA (2007).
   Google Scholar
• Bristow JD, Honour AJ, Pickering GW, Sleight P, Smyth HS. Diminished baroreflex sensitivity in high blood pressure. Circulation 39(1), 48–54 (1969).
   PubMed Web of Science ®Google Scholar
• Heusser K, Tank J, Luft FC, Jordan J. Baroreflex failure. Hypertension 45(5), 834–839 (2005).
   PubMed Web of Science ®Google Scholar
• Bilgutay AM, Wingrove RC, Simmons RL, Dahlstrom IJ, Lillehei CW. A new concept in the treatment of hypertension utilizing an implantable electronic device: ‘Baropacer’. Trans. Am. Soc. Artif. Intern. Organs 10, 387–395 (1964).
   PubMedGoogle Scholar
• Bilgutay AM, Lillehei CW. Treatment of hypertension with an implantable electronic device. JAMA 191, 649–653 (1965).
   PubMedGoogle Scholar
• Neistadt A, Schwartz SI. Effects of electrical stimulation of the carotid sinus nerve in reversal of experimentally induced hypertension. Surgery 61(6), 923–931 (1967).
   PubMed Web of Science ®Google Scholar
• Griffith LS, Schwartz SI. Reversal of renal hypertension by electrical stimulation of the carotid sinus nerve. Surgery 56, 232–239 (1964).
   PubMedGoogle Scholar
• Agishi T, Temples J, Peirce EC 2nd. Electrical stimulation of the carotid sinus nerve as an experimental treatment of hypertension. J. Surg. Res. 9(5), 305–309 (1969).
   PubMedGoogle Scholar
• Neufeld HN, Goor D, Nathan D, Fischler H, Yerushalmi S. Stimulation of the carotid baroreceptors using a radio-frequency method. Isr. J. Med. Sci. 1(4), 630–632 (1965).
   PubMedGoogle Scholar
• Myers GH, Parsonnet V, Holcomb W, Zucker IR, Lewin G. An experimental radio-frequency carotid-sinus pacemaker. Med. Res. Eng. 7(1), 13–16 (1968).
   PubMedGoogle Scholar
• Michaelis LL, Gilmore JP. Renal effects of electrical stimulation of the carotid sinus nerve. Surgery 65(5), 797–801 (1969).
   PubMedGoogle Scholar
• Resnicoff SA, Harris JP, Hampsey JP, Schwartz SI. Effects of sinus nerve stimulation on arterial resistance and flow patterns of specific vascular beds. Surgery 66(4), 755–761 (1969).
   PubMedGoogle Scholar
• Carlsten A, Folkow B, Grimby G, Hamberger CA, Thulesius O. Cardiovascular effects of direct stimulation of the carotid sinus nerve in man. Acta Physiol. Scand. 44(2), 138–145 (1958).
   PubMedGoogle Scholar
• Bilgutay AM, Lillehei CW. Surgical treatment of hypertension with reference to baropacing. Am. J. Cardiol. 17(5), 663–667 (1966).
   PubMed Web of Science ®Google Scholar
• Schwartz SI, Griffith LS, Neistadt A, Hagfors N. Chronic carotid sinus nerve stimulation in the treatment of essential hypertension. Am. J. Surg. 114(1), 5–15 (1967).
   PubMed Web of Science ®Google Scholar
• Scheffers IJ, Kroon AA, de Leeuw PW. Carotid baroreflex activation: past, present, and future. Curr. Hypertens. Rep. 12(2), 61–66 (2010).
   PubMed Web of Science ®Google Scholar
• Lohmeier TE, Iliescu R. Chronic lowering of blood pressure by carotid baroreflex activation: mechanisms and potential for hypertension therapy. Hypertension 57(5), 880–886 (2011).
   PubMedGoogle Scholar
• Schmidli J, Savolainen H, Eckstein F et al. Acute device-based blood pressure reduction: electrical activation of the carotid baroreflex in patients undergoing elective carotid surgery. Vascular 15(2), 63–69 (2007).
   PubMedGoogle Scholar
• Heusser K, Tank J, Engeli S et al. Carotid baroreceptor stimulation, sympathetic activity, baroreflex function, and blood pressure in hypertensive patients. Hypertension 55(3), 619–626 (2010).
   PubMed Web of Science ®Google Scholar
• Scheffers IJ, Kroon AA, Schmidli J et al. Novel baroreflex activation therapy in resistant hypertension: results of a European multi-center feasibility study. J. Am. Coll. Cardiol. 56(15), 1254–1258 (2010).
   PubMed Web of Science ®Google Scholar
• Krum H, Schlaich M, Sobotka P, Scheffers I, Kroon AA, de Leeuw PW. Novel procedure- and device-based strategies in the management of systemic hypertension. Eur. Heart J. 32(5), 537–544 (2011).
   PubMed Web of Science ®Google Scholar
• Bisognano JD, Bakris G, Nadim MK et al. Baroreflex activation therapy lowers blood pressure in patients with resistant hypertension: results from the double-blind, randomized, placebo-controlled Rheos Pivotal Trial. J. Am. Coll. Cardiol. 58(7), 765–773 (2011).
   PubMed Web of Science ®Google Scholar
• Bisognano JD, Kaufman CL, Bach DS, Lovett EG, de Leeuw P; DEBuT-HT and Rheos Feasibility Trial Investigators. Improved cardiac structure and function with chronic treatment using an implantable device in resistant hypertension: results from European and United States trials of the Rheos system. J. Am. Coll. Cardiol. 57(17), 1787–1788 (2011).
   PubMed Web of Science ®Google Scholar